J Rheum Dis.  2013 Jun;20(3):137-139. 10.4078/jrd.2013.20.3.137.

H1N1 Influenza Vaccination Response in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients

• Yoo WH

• KMID: 2222751
• DOI: http://doi.org/10.4078/jrd.2013.20.3.137

Abstract

No abstract available.

MeSH Terms

Arthritis, Rheumatoid
Humans
Influenza, Human
Lupus Erythematosus, Systemic
Vaccination

Reference

References

1. Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-re-lated morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007; 26:663–70.

2. Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep. 2007; 56:1–54.

3. Kim JH, Choi HN, Kim SH, Lee H, Park SH, Kim SK, et al. Pandemic H1N1 Influenza vaccination responses in rheumatoid arthritis and systemic lupus erythematosus patients. J Rheum Dis. 2013; 20:87–93.

4. Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease–a prospectively controlled vaccination study. Rheumatology (Oxford). 2012; 51:695–700.

5. Del Porto F, Laganà B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine. 2006; 24:3217–23.

6. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003; 362:1733–45.

7. Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al. H1N1 Study Group. Impact of syn-thetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011; 63:1486–96.

8. Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2012; 39:167–73.

9. Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 2002; 29:2555–7.

10. Saad CG, Borba EF, Aikawa NE, Silva CA, Pereira RM, Calich AL, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis. 2011; 70:1068–73.

11. Urowitz MB, Anton A, Ibanez D, Gladman DD. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011; 63:1517–20.

12. Abu-Shakra M, Press J, Sukenik S, Buskila D. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol. 2002; 21:369–72.

13. Schiffer L, Kümpers P, Davalos-Misslitz AM, Haubitz M, Haller H, Anders HJ, et al. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transplant. 2009; 24:3708–12.